Group 1 - Shenzhen companies are increasingly exploring emerging markets, with a focus on diversifying their business operations, particularly in the oral care consumer goods sector [1] - Financial institutions in Shenzhen are evolving into resource linking and overseas service stations, providing customized and comprehensive solutions for companies venturing abroad [1][2] - The demand from companies for services related to overseas logistics, market access, compliance, tax policies, cross-border financing, and localization is growing [2][3] Group 2 - Banks are not only facilitating resource matching but are also directly involved in advising companies on their overseas operations, offering both financial and non-financial services [3] - The international market is becoming a significant growth area for Chinese commercial banks, with examples like ICBC Brazil focusing on cross-border settlements and trade financing [3][4] - The use of the Renminbi in international trade is increasing, with over 50% of some Latin American countries starting to adopt it for trade and investment, benefiting Shenzhen's private enterprises [3][4] Group 3 - Shenzhen's cross-border insurance services are expanding to cover the entire process of companies going abroad, with a focus on risk mitigation [5] - Common risks faced by companies include exchange rate fluctuations, geopolitical changes, and buyer defaults, which are often excluded from standard insurance coverage [5] - The "Big Protection" insurance program supports small and medium-sized export enterprises, with 22,000 companies signing up in 2024, facilitating exports worth $90.91 billion, a 27.5% increase [5][6]

Core Viewpoint - Wuhan Dazhong Dental Medical Co., Ltd. has submitted a second application for listing on the Hong Kong Stock Exchange, marking another attempt at capitalizing after its first application lapsed due to not completing the listing within six months [1][2]. Business Layout and Market Position - Founded in 2007 by Yao Xue, the company operates 92 medical institutions, including 4 hospitals and 80 outpatient departments, primarily in Hubei and Hunan provinces, establishing a community-centered service network [1]. - According to Frost & Sullivan, Dazhong Dental ranks first among private dental service providers in Central China, with a market share of approximately 2.6% based on 2023 revenue [1]. - The company's main business segments include comprehensive dental services, dental implant services, and orthodontic services, with comprehensive dental services accounting for over 50% of total revenue [1]. - The company has demonstrated strong customer retention, with a revisit rate increasing from 75.3% in 2022 to 79.6% in 2024 [1]. Financial Performance and Challenges - The company has experienced revenue fluctuations, with revenues of 409 million yuan, 442 million yuan, and 407 million yuan from 2022 to 2024, respectively [2]. - Net profit attributable to shareholders was 43.3 million yuan, 50.1 million yuan, and 41.9 million yuan for the same years, with a noticeable decline in 2024 [2]. - The gross profit margin decreased from 38.1% in 2023 to 37.4% in 2024 [2]. - The decline in performance is attributed to slow economic recovery post-pandemic and intensified competition in the dental service industry, leading to a drop in average transaction prices across all main business segments [2]. - The average cost of dental implant services fell over 30%, from 8,460 yuan in 2022 to 5,767 yuan in the first half of 2024, influenced by national procurement policies [2]. - Prior to the listing application in September 2024, original investors, including CITIC Securities, chose to exit, leading the company to repurchase 8.3793 million shares for 121 million yuan [2].

Core Viewpoint - Wuhan Dazhong Dental Medical Co., Ltd. (Dazhong Dental) has submitted its second listing application to the Hong Kong Stock Exchange, aiming to raise funds for expansion and upgrades in the Central China region [1][2]. Company Overview - Dazhong Dental was founded in 2007 by Yao Xue and operates 92 institutions, including 4 hospitals, 80 outpatient departments, and 8 clinics, primarily in Hubei and Hunan provinces [2][3]. - The company holds the largest market share of approximately 2.6% among private dental service providers in Central China, based on 2023 revenue [2]. Business Model and Services - Dazhong Dental focuses on community-centered dental care, offering comprehensive dental services, dental implant services, and orthodontic services [2][3]. - The revenue from comprehensive dental services accounts for over 50% of the total revenue, with dental implants and orthodontics being the second and third largest revenue sources, respectively [2]. Financial Performance - Dazhong Dental's revenue for 2022, 2023, and 2024 was reported as 409 million yuan, 442 million yuan, and 407 million yuan, respectively, with net profits of 43.3 million yuan, 50.1 million yuan, and 41.9 million yuan [3]. - The gross profit margin decreased from 38.1% in 2023 to 37.4% in 2024 [3]. Market Challenges - The company faced challenges in 2023-2024 due to slower-than-expected economic recovery post-pandemic, leading to consumer spending downgrades and increased competition among dental service providers [5][14]. - The average transaction price for Dazhong Dental's three main business segments has declined [5]. Investment and Financing - Dazhong Dental has previously received investments from institutions such as CITIC Securities and Zhongyuan Jiupai, but these investors exited or reduced their stakes before the listing application [12][13]. - The company repurchased 8.3793 million shares from these investors for a total of 121 million yuan, citing differing opinions on the company's development as the reason for the exits [13]. Industry Context - The Hong Kong government is actively promoting the return of Chinese concept stocks, and the Hong Kong Stock Exchange has simplified the listing process, which may benefit Dazhong Dental [14]. - However, the company may face increased operational pressure due to ongoing medical procurement policies and intensified competition from larger players like Tongce Medical [14].

近期，多家权威媒体聚焦中国企业在防蛀原料奥拉氟成分上的技术突破。5月8日，央视网《世界微笑日 特别节目》对国内儿童口腔护理品牌兔头妈妈首次报道，展示了其自主合成的高纯度奥拉氟，在多方检 测下，防蛀性能远超进口。 在中国5岁儿童乳牙龋患率高达70.9%的现状下，这一重大防蛀科技突破后续引发极目新闻、新京报、 凤凰网等权威媒体密集关注，争相报道其背后的科研突围之路。 奥拉氟，正是国内近年来因防蛀性能优异而非常火热的成分。其源于欧洲上世纪50年代末60年代初，距 今已有60年应用历史。据公开资料显示，奥拉氟因其特殊分子结构带来了特殊的性能，如优异的延展 性，能在牙齿表面快速铺展形成一层保护膜；另外包裹性上，可以跟牙齿表面和口腔的软组织进行结 合，不易被食物带走，对牙齿可以长效保护；此外它在促进牙齿再矿化、增加抗酸蚀能力和抑菌能力 上，都有很好的表现。 目前市面上奥拉氟牙膏丰富，但备受追捧的奥拉氟原料实际上长期依赖进口。兔头妈妈研发科学家、浙 江大学高分子化学与物理博士王莎莎在接受极目新闻采访时提到，"在去年以前，全球具有生产奥拉氟 能力的企业只有三家，全部在欧洲。""为了产品升级，我们希望能够技术共享，但被对方拒绝 ...

丨 2025年6月3日 星期二 丨 NO.1 华熙生物、巨子生物舆论风波升级，美妆博主回应：不认可巨子生物的说法 每经记者｜甄素静 每经编辑｜董兴生 近日，浙江海圣医疗器械股份有限公司IPO申请获北交所受理，中信证券担任保荐机构。招股书显示， 海圣医疗专注于麻醉、监护类医疗器械的研发、生产和销售，产品广泛应用于麻醉科、ICU等临床科 室。 点评：海圣医疗冲刺北交所IPO，专注于麻醉监护器械研发等，产品应用于多临床科室，若成功上市， 或将借助资本加速技术创新与市场拓展。 NO.4 和美药业递表港交所 据港交所5月29日披露，赣州和美药业股份有限公司向港交所主板递交上市申请。和美药业于2002年成 立，截至2025年5月21日，和美药业已开发7个小分子候选药物，针对具有高度未满足需求的自身免疫和 肿瘤疾病。其中4种候选药物处于II期、III期临床试验或NDA阶段，适用于12种适应证。 6月1日晚，华熙生物在微信公众号发表长文支持"大嘴博士"（郝宇）。当日深夜，巨子生物在微信公众 号发布了一份声明，称有关"可复美"未添加重组胶原蛋白的争议，5月30日公司收到了来自"大嘴博 士"所用检测机构的道歉声明，并贴出了检验机 ...

将投中网设为"星标⭐"，第一时间收获最新推送 速览投资风口，掌握资本律动。 作者丨 长风 来源丨 东四十条资本 大家好，我是长风。今天给大家带来上周资本市场的专业投研信息。 焦点回顾： 新消费赛道，消费机器人受欢迎。 上周，国内智能机器人企业乐享科技官宣完成亿元级天使+轮 融资，由锦秋基金领投，老股东经纬创投、绿洲资本、Monolith超额加投，光源资本跟投，光源 资本担任独家财务顾问。此外，地平线机器人旗下地瓜机器人宣布完成1亿美元A轮融资。由高瓴 资本、五源资本、线性资本、和暄资本、九合创投、Vertex Growth、砺思资本、敦鸿资产、沸 点资本、梅花创投、黄浦江资本等投资机构共同参投。 硬科技赛道，新材料又有钱了。 上周，国瑞新材近日宣布完成数亿元B轮融资。此次融资由深创 投、华映资本、国泰君安创新投、众行资本、中天辽创、德鸿资本、深智城产投、梧桐树资本共同 投资完成。5月30日消息，芯源新材料完成C轮融资，由小米智造股权投资基金合伙企业（有限合 伙）独家投资。 大健康赛道，口腔医疗受重视。 上周，口腔数字化企业铖联科技宣布成功完成近两亿元人民币的 B+轮融资。本轮融资由达晨资本和高特佳投资联合领投 ...

5月30日晚间，霸王茶姬（NASDAQ:CHA）发布2025年一季报，这也是其上市后的首份财报。财报显示，截至一季度末，霸王茶姬全球门店数达到6681 家，季度总 GMV 达82.3亿元，同比增长38%。本季度实现总净收入33.9亿元，同比增长35.4%；实现净利润6.77亿元，同比增长13.8%。在本次财报中，霸 王茶姬首次披露了其海外市场的季度总 GMV 和各地区的门店分布情况。根据财报，本季度霸王茶姬海外市场总 GMV 达到1.78亿元，同比增长85.3%。截至 一季度末，霸王茶姬共有169家海外门店，其中157家分布在马来西亚、10家分布在新加坡，2家位于泰国。（证券时报） 快手财报：海外业务首次盈利，AI 收入超过1.5亿 访问36氪出海网站 letschuhai.com ，获取更多全球商业相关资讯。 头条大事 活动｜直接对话印尼政府代表，500亿美元医疗市场如何入局？ 为助力中国企业更好地把握印尼市场机遇，36氪出海将携手印尼市场拓展与创新服务平台 Lestari 推出系列主题活动。首场活动于6月4日下午2:00在线上举 办，将聚焦印尼500亿美元医疗市场，邀请印尼投资协调部、卫生部官员代表解读医 ...

5月29日，港交所官网显示，口腔医疗服务机构武汉大众口腔医疗股份有限公司（下称"大众口腔"）向港交所递交IPO申请， 海通国际为独家保荐人。 值得一提的是，大众口腔于2024年11月29日所递交的港股招股书已满6个月，于2025年5月29日刚刚失效。 IPO日报注意到，作为华中地区民营口腔医疗服务提供商第一位，大众口腔2024年收入与利润同比双降，曾获得中信证券投 资、中元九派、致道资本等机构的投资，但这些原始机构投资方基本在IPO前夕清仓离场。 AI制图 2024年收入与利润双双下滑 大众口腔成立于2007年由姚雪和沈洪敏创立,提供以社区为中心的口腔医疗护理，包括综合牙科诊疗服务、口腔种植服务及口 腔正畸服务，可满足全年龄段客户的口腔健康需求。大众口腔曾挂牌新三板，但于2018年主动摘牌。 根据咨询机构弗若斯特沙利文的资料，按2023年所得收入计，公司在华中地区所有民营口腔医疗服务提供商中居第一位，占 市场份额约2.6%。按截至2023年12月31日的牙椅数量计，公司于高度分散且竞争激烈的中国民营口腔医疗服务行业中亦位居第五 位。 此外，2024年，大众口腔的毛利率为37.4%，净利率为15.4%。 公司的 ...

通策医疗股份有限公司 2024 年年度股东会资料 通策医疗股份有限公司 会议资料 通策医疗股份有限公司董事会 通策医疗股份有限公司 2024 年年度股东会资料 通策医疗股份有限公司 议案 2 《通策医疗股份有限公司 2024 年度董事会工作报告》； 议案 3 《通策医疗股份有限公司 2024 年度利润分配方案》； 议案 4 《通策医疗股份有限公司 2024 年度财务决算报告》； 一、程序文件 二、提交股东会审议表决的议案 议案 1 《通策医疗股份有限公司 2024 年年度报告》和《通策医疗股份有限公司 2024 年年度报告摘要》； 议案 5 《通策医疗股份有限公司关于续聘会计师事务所的议案》； 议案 6 《通策医疗股份有限公司 2024 年度监事会工作报告》； 议案 7 《通策医疗股份有限公司关于修订 <公司章程> 的议案》。 通策医疗股份有限公司 2024 年年度股东会资料 通策医疗股份有限公司 一、现场会议时间： 2025 年 6 月 5 日（星期四）下午 14 时 30 分。 网络投票时间：采用上海证券交易所交易系统投票平台的投票时间为股东会 召开当日的交易时间段；通过上海证券交易所互联网投票平台的投票 ...

Financing Information - Chenglian Technology, a leading company in the dental digitalization sector, has successfully completed a B+ round financing of approximately 200 million RMB, led by well-known investment institutions Dacheng Capital and Gaotejia Investment [1][2] - After this round of financing, the total financing amount for Chenglian Technology will exceed 500 million RMB [1] Market Context - This financing represents the largest amount raised in the domestic dental medical market in 2025 so far [2] - The trend of capital focusing on upstream manufacturers in the dental industry has become increasingly evident over the past three years, as investments shift from high-return projects to those with longer return cycles [10] Company Achievements - Chenglian Technology was included in the Ministry of Industry and Information Technology's list of "specialized and innovative small giant" enterprises in 2023 and has made it onto two national-level lists: "2024 China Invisible Unicorn Enterprises Top 500" and "2024 Annual Patent Intensive Product List" [4] - The company has developed a series of products, including the Yake Mei® laser cladding titanium framework, and has initiated a national alliance plan for digital dental factories [5] Global Expansion - Chenglian Technology has expanded its business to over 30 countries and regions globally, establishing multiple overseas subsidiaries and signing contracts with over 300 cloud factories [6] - A significant partnership with Hanruixiang aims to promote dental digital manufacturing services in the European market, leveraging Hanruixiang's extensive global presence [6][8] Market Potential - The estimated market value of Chenglian Technology is around 4 billion RMB, positioning it as a potential unicorn candidate in the dental industry [9] - The dental market's gross profit margins vary significantly, with upstream markets showing potential for higher profit margins compared to the saturated downstream market [10][11]